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Topic Relevance by Timeline 
Summary 
● In recent years there has been an increasing need for investigators to secure alternative 
sources of funding, and nonprofit organizations have become integral parts of the research 
and development process. 
● Venture philanthropy is a relatively new concept of cooperation in which nonprofits not 
only fund research but also take a businesslike approach to product development, commer-
cialization, and collaboration with industry partners. 
● Potential opportunities that come with nonprofit funding can include better patient access, 
more early funding for research and development, and increased networking opportunities. 
● Investigators must be prepared for potential pain points such as managing conflicts of 
interest, managing intellectual property, and ensuring prior art is accounted for during the 
application process. 
● With proper management and transparency, involvement with a nonprofit foundation has 
the potential to be greatly beneficial to both the investigator and the foundation. 
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Introduction 
Individual research centers and universities are often confronted with the predicament of providing 
enough funding to generate promising research and also creating an environment where a new 
therapy can be tested and potentially brought to market. The field of science, specifically medical 
research and therapy development, is notorious for a lack of integration and sharing of data/re-
sources. This is a hindrance to the overall goal of developing therapies and technologies that can 
have an impact on human health because it creates an environment of isolation in research. Many 
researchers and their associated universities do not have the resources to develop and license new 
technology, as it is an expensive and potentially legally complicated endeavor. During times of 
decreasing government funding and tightened budgets, it becomes more important than ever to 
have additional sources of funding available. Nonprofit organizations and foundations have more 
recently stepped into the arena of research collaboration to function as the much-needed financial 
and organizational guide in the effort to get a therapy “from bench to bedside.” 
Benefits and History of Research Funding 
Securing funding for research and development is not a new challenge to the scientific community. 
In pre–World War II United States, researchers commonly relied on contributions from universi-
ties and philanthropists, as money from the U.S. government was mostly directed toward agricul-
ture and aeronautics (Jahnke). Prewar concerns in the 1940s caused the U.S. government to direct 
funding toward research and development in science, medicine, and technology. While the 
National Science Foundation (NSF) and the National Institutes of Health (NIH) are both 
government-run organizations that award grants for research and development, funding from those 
sources is highly competitive, and the amount of funds available depends on budget allocations 
from the government. Funding from nonprofits and foundations came from businessmen-turned-
philanthropists such as Andrew Carnegie and John D. Rockefeller, Sr., via their own nonprofit 
organizations. Indeed, the Rockefeller Foundation made its first grant in 1913 to the American 
Red Cross, and this established a legacy of funding science and medical research that still continues 
today (“Our History—The Rockefeller Foundation”). Over time, more nonprofits and foundations 
were established in response to a specific problem that required attention, such as the Cystic 
Fibrosis (CF) Foundation, and these foundations, in turn, began seeing the necessity of providing 
funding to researchers who were working on the problems that the foundations wished to address. 
Perhaps the biggest hurdle that researchers have faced in the past is taking promising research from 
bench to bedside via funding for clinical trials, drug development, and guidance through the regu-
latory process. The importance of foundation involvement in funding research and development 
to this end cannot be overstated. According to the Cystic Fibrosis Foundation, the idea of “venture 
philanthropy” was started in 1998 by the CF Foundation to initiate the development of promising 
research with drug companies that had previously been reluctant to get involved in research when 
large profits were not guaranteed. This led to the creation of several drugs targeted toward CF and, 
most notably, in 2012 to a drug targeting the underlying cause of CF. This type of collaboration 
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has become more commonplace, as organizations can not only guide promising research in the 
right direction, but they also stand to gain intellectual property (IP) ownership (see the chapter 
“Intellectual Property: Ownership and Protection in a University Setting”); this can result in more 
foundation funding for research on the back end if the foundation opts to sell its rights, as the CF 
Foundation did in 2014 (“Cystic Fibrosis Foundation”). 
 
In addition to nonprofits that fund disease-specific research, there are organizations, such as the 
Bill and Melinda Gates Foundation, that direct funding toward broader issues like access to 
healthcare and education in developing nations. Poverty-stricken areas require innovative solu-
tions to a lack of basic needs such as clean water, sustainable farming practices, and disease 
eradication. Rather than implementing past approaches that had limited accountability and focus, 
the Gates Foundation aims to tackle problems with strategies specific to the problem at hand, and 
this also extends to their funding practices, which are considered by the Gates Foundation to be 
investments. A businesslike approach is also taken with grants, which are geared toward fiscal 
responsibility and productivity, and will most likely not be used to generate patents for profit. An 
example of this is a $1.3 million grant awarded to the University of Wisconsin–Madison in 2008 
that funded research into influenza pandemics. This research involved a collaboration with 
Lentigen Corp and it was agreed that any intellectual property generated during the study would 
be donated to the international research community (“WARF, UW-Madison Influenza Researcher, 
Lentigen Agree to Donate Technology”). According to the Gates Foundation, global access is a 
stipulation for any IP or product developments made with funding from the foundation; the new 
product or IP may be disseminated by a for-profit collaborator to the developed world but it must 
be made available globally “to the people that need them most” (“Bill & Melinda Gates Founda-
tion”). 
 
An additional relevant example of nonprofit venture philanthropy is the Parker Institute, which 
was founded and funded by Napster founder Sean Parker. The goals of the Parker Institute are 
many and varied, but the overall mission is to speed the discovery of life-saving technologies. To 
do this, the institute partnered with several world-renowned research centers and the world’s best 
researchers to provide not only financial support but also general management to streamline and 
guide crucial new research (McCullough). A key component of this large-scale collaboration is 
the sharing of data and ideas from labs that may formerly have had no connection. The Parker 
Institute is harnessing its considerable resources to put promising research in the best position to 
succeed by partnering with companies in the biotech and pharma industry, providing expertise on 
IP development and licensing, and managing clinical trials. The concept of such a collaborative 
environment with the availability of funds may prove to be revolutionary to the field of cancer 
research, and it could also change the way that new technologies are developed and licensed com-
mercially. The Parker Institute saw the promise of a specific type of technology, cancer 
immunotherapy in this instance, and in the process of investing financially in this new technology 
they have also built a bridge between academia and industry at a time when industry-funded 
research in an academic setting is still in its infancy. The Novartis-Penn alliance is an example of 
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a very recent collaboration between industry and academia that has been successful thus far, and 
the Parker Institute seeks to foster similar collaborations in the future. Alongside financial support, 
providing an environment in which similar collaborations may happen is perhaps one of the most 
important functions of nonprofit foundation involvement (Kannan). Of note is that the Parker In-
stitute may request co-ownership of IP; this is discussed in more detail in later sections. 
Other Benefits of Joining a Nonprofit or Foundation 
There are many motivating factors in addition to funding that could encourage researchers to 
become involved with a nonprofit or foundation. Foundations and nonprofits are excellent sources 
of patient access, given that they most often have outreach to patients and their families, especially 
larger organizations such as the ALS Association. These large-scale nonprofits have vast resources 
and make community outreach and advocacy a priority in order to generate interest and funds. 
With a revenue of over $68 million for FY2016, the ALS Association has the ability to fund 
promising research and connect families with potential therapies (“The ALS Association”). Even 
smaller nonprofits, such as the Emily Whitehead Foundation, have immense outreach abilities that 
can connect patients and their families with researchers in need of subjects for clinical studies. Not 
only is access to patients incredibly valuable, but researchers also benefit from the trust of the 
patients’ families. Gaining trust from a parent to enroll their child on a clinical trial is easier when 
the parents have the comfort of knowing that a reputable foundation is endorsing the clinical trial 
and the associated researchers. Alex’s Lemonade Stand Foundation (ALSF) is an example of im-
proving outreach while also improving outcomes with focused research grants (“Alex’s Lemonade 
Stand Foundation for Childhood Cancer”). According to the Michael J. Fox Foundation, 80% of 
clinical trials finish late because of difficulty with research subject recruitment, and one-third will 
never even begin due to a lack of research subject recruitment (“Clinical Trials 101: Understanding 
Clinical Trials”). These statistics highlight the importance of patient access for product 
development. With a dedicated page for grants and a browsing tool for sponsored research on its 
website, the ALSF makes it clear that support for researchers is a number one priority, and this 
allows families to understand the research that is happening and the clinical trials that are available. 
While an organization such as ALSF may not be able to award grants large enough for a startup 
company to run on, early seed funding is crucial for getting started and for advancing research in 
an academic setting. Larger organizations such as the Juvenile Diabetes Research Foundation 
(JDRF) are able to make bigger moves financially and have made financial commitments to com-
panies that are pursuing innovative solutions to health problems. For example, the JDRF has 
recently announced a $42 million venture philanthropy fund geared toward “funding the best high-
impact type-1 diabetes commercial opportunities” (Moses). The JDRF expands its reach even 
further by organizing symposium events and conferences for anyone involved in the field of 
diabetes research. Networking is a value added from foundations that cannot be overlooked, as it 
can provide access to new data and ideas as well as the opportunity for researchers to connect and 
share resources (“JDRF Grant Center”). Furthermore, a letter of support or demonstration of 
engagement with a patient-facing nonprofit/foundation may be viewed favorably by a federally 
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sponsored scientific review group, such as an NIH study section, and thus be valuable for other 
grant applications submitted by an academic entrepreneur. 
 
When engaging with a nonprofit, it is important to remember the responsibilities and expectations 
that can come along with funding. When seeking out a nonprofit with which to partner, it is 
important to ensure that there is an alignment of goals and that the nonprofit is seeking to contribute 
to research in a specific area. For example, the Juvenile Diabetes Research Center is an excellent 
resource for anyone with an interest in researching areas of metabolism, pancreatic function, or 
immunotherapy; however, it must be considered that funding is only provided for research that is 
targeted against type 1 diabetes (“JDRF—Type 1 Diabetes Research Funding and Advocacy”).  
 
There are many opportunities to make contacts and network with potential collaborators when 
searching for nonprofit partners (see the chapter “Forming and Maintaining Meaningful 
Partnerships Between Academic Scientists and Corporations”). Depending on the area of research, 
these include numerous national and regional research symposiums as well as conferences, many 
of which are designed specifically for the purpose of networking. For example, the CF Foundation 
sponsors a North American CF Conference each year that brings together thousands of scientists 
and clinicians for the purpose of education and idea exchange (“Cystic Fibrosis Foundation”). 
Upon securing a nonprofit organization with which to work, it is important to recognize that the 
nonprofit may be on a national or global scale, and this could require participation in specific 
events or campaigns. The foundation may require attendance or presentations at conferences or 
participation in publicity events and public outreach campaigns, in addition to other methods of 
oversight. As an example, Alex’s Lemonade Stand Foundation states in their grants policy that a 
progress report must be submitted by the principal investigator each year, and this involves sub-
mitting details of budget expenditures as well as research progress, all of which is reviewed by the 
ALSF scientific advisory board (“Alex’s Lemonade Stand Foundation for Childhood Cancer”). 
Additionally, a nonprofit will have policies on information and IP that must be adhered to; for 
example, the JDRF remains committed to disseminating scientific information to the public and 
requires that anyone using JDRF resources also agrees “to the publication and dissemination of all 
information and materials developed” (“JDRF Grant Center”). These are very important aspects 
to consider when deciding to partner with a nonprofit organization, and it is crucial for researchers 
to perform due diligence and fully understand the expectations when accepting foundation part-
nerships. 
Challenges When Collaborating with a Nonprofit or 
Foundation 
While the advantages of advancing research via collaboration with a nonprofit or foundation are 
obvious, there are also challenges that will go along with it. When advancing promising research 
and developing potential therapies or technology, there are always financial, regulatory, and legal 
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issues at hand, and this fact is not negated due to the involvement of a foundation. Intellectual 
property is an important aspect of scientific entrepreneurship (covered in more detail in other chap-
ters), and IP is a potential challenge when interacting with a nonprofit or foundation (see the 
chapters “Intellectual Property: Ownership and Protection in a University Setting” and 
“Intellectual Property: Commercializing in a University Setting”). In the more recently developed 
area of venture philanthropy, large foundations and nonprofits with significant financial contribu-
tions to research are seeking to benefit from commercially successful therapies paid for (at least in 
part) by the foundation itself. See Figure 1 for a comparison of traditional venture capital investing 
versus the venture philanthropy model that is being utilized by organizations such as the Cystic 
Fibrosis Foundation. 
 
Obviously, the topics of intellectual property and the associated royalties that are due to the in-
vesting partner (e.g., the Cystic Fibrosis Foundation) are critical issues for a researcher or startup 
company to consider. The foundation making the investment will inevitably want to also see 
profits from any commercially successful venture, and, according to Kristin Schneeman of the 
think tank FasterCures, nonprofits and foundations almost always opt to give royalty-bearing 
grants rather than making equity investments (Wolinsky). As noted in Nature Magazine, 
charities involved in venture philanthropy are providing crucial funding at a point when the risk 
is greatest, and they expect a return on their money (Ledford). 
 
Figure 1. Revenue Flow to Funders in a Venture Philanthropy Model vs. Traditional 
Investment Model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: Items with no background are the source of funding. Green backgrounds are forms of 
funding. Blue backgrounds are the output of the source and form of funding. Profits/royalties are 
also returned to the academic entrepreneur and their institution, but the terms vary considerably 
depending upon the details of their contractual arrangements and are thus not shown here. 
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In addition, nonprofits and foundations that get financially involved in commercially directed 
ventures will often demand that an interruption license is signed in order to prevent IP from 
sitting unused by the startup; they also may resist getting financially involved in the various 
indirect costs associated with establishing IP and bringing it to market (Ledford). Another 
financial considerations is that some foundations do not allow researchers/research institutions to 
include overhead in their grants, or they place very low caps on the overhead. 
  
Conflict of interest is another challenge involved in nonprofit-sponsored research, for several rea-
sons (see the chapter “Understanding Conflict of Interest for Academic Entrepreneurs”). First, 
maintaining the trust of the patient/family base is of great importance to a charity and it is possible 
that becoming involved in venture philanthropy could jeopardize that trust. On the one hand, 
patients expect their respective foundations to use financial resources wisely and also to act as an 
advocate for the patients and their families. This includes fundraising and creating resources as 
well as utilizing those funds in a manner that will best help current and future patients. An example 
of how a conflict of interest can arise is the following scenario: A nonprofit makes financial con-
tributions to the development of a drug with expectations of IP licensing revenue, but when the 
drug comes to market, the price is so high that the patients supporting the foundation experience 
financial hardships or have limited access (see Figure 2 below), while the foundation may have an 
incentive to encourage higher pricing since IP licensing revenue is usually tied to pricing. This is 
a hypothetical scenario; in general, one of the major advantages of working with philanthropic 
foundations is that their goals often prioritize the patients, and are better aligned with a hospital 
and health-related research than private sector investors and partners. Their desired outcomes often 
are to improve the lives of patients regardless of the financial return on investment (ROI). 
  
Figure 2. Potential Conflict of Interest Cycle for Charities. 
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To attempt to avoid the scrutiny that goes along with intellectual property benefits, nonprofits must 
certainly have a clear conflict of interest policy in place, as well as transparency with financial 
documents. In this instance, if a nonprofit wishes to invest and see returns as a normal for-profit 
business, then it is necessary for it to function as such, which requires a clear leadership hierarchy 
and honesty with the patients and families who provide grassroots financial support. An additional 
subject for consideration by all parties is the disclosure and the management of IP, as well as 
potential prior art issues. As stated by the Oklahoma State University Technology Development 
Center, grant applications can be recognized legally as prior art, and this is crucial to any investi-
gator and/or nonprofit with an interest in patent filing and IP development (“Grant Applications as 
Prior Art”). It is extremely important for all parties involved in funding to understand the 
ramifications of filing grant applications as well as the practices of seeking patents and developing 
technology; for example, if a nonprofit or foundation posts grant applications on their website, this 
may represent prior art and compromise future IP (see the chapter “Does My Invention Already 
Exist? Conducting a Patent / Prior Art Search”). The applicant should read all disclosure 
information provided by the foundation prior to submitting any information; while most large 
grant-awarding foundations will provide disclosure and confidentiality policies on their website, 
applicants should always work with the appropriate foundation contact to clarify any questions. 
This subject is another matter that requires some forethought and research on the part of the appli-
cant prior to becoming legally and financially involved with a nonprofit. 
Conclusion 
In an environment of ever-changing financial states and changes to organizational structures and 
regulations, it is important for researchers to explore all avenues for funding opportunities. Non-
profit foundations can be an excellent resource for investigators seeking funding for research and 
development. As with most funding sources, there are legal and financial points to consider prior 
to getting involved with a foundation or nonprofit; however, most potential pain points can be 
dealt with or avoided as long as there is transparency from all parties throughout the process. 
Gaining support from a foundation can have many positive impacts on research beyond simply 
providing funding. A well-regarded and well-funded foundation may have resources that can pro-
vide investigators with more networking opportunities, increased interaction with partner labs and 
organizations, increased access to patients, guidance through the regulatory process, and industry 
connections. These numerous benefits could be the difference between simply having a concept 
and being able to conduct the necessary research to fully develop that concept into a marketable 
drug or device that can impact human health. Gaining support from a nonprofit could be a mutually 
beneficial relationship for the investigator and the foundation that could provide long-term returns 
both developmentally and financially. 
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Resources 
1. Open Education Database: 
http://oedb.org/ilibrarian/100_places_to_find_funding_your_research/. A website 
providing information and links to potential funding sources. 
2. United States Patent and Trademark Office website: https://www.uspto.gov/.nformation 
on patents, intellectual property, and additional resources for inventors. 
3. Science Philanthropy Alliance: http://www.sciencephilanthropyalliance.org/. A 
community of philanthropists committed to funding science. 
4. Office of Sponsored Project Administration at Southern Illinois University, Carbondale: - 
https://ospa.siu.edu/find/external-funding/other-funding.php. A university website 
containing a list of foundations and nonprofit funding agencies.  
5. GuideStar, Directory of Charities and Nonprofit Organizations: 
http://www.guidestar.org/nonprofit-directory/health/diseases-disease-research/1.aspx. An 
extensive list of charitable foundations. 
6. Venture Philanthropy Strategies to Support Translational Research: Workshop Summary  
a. Institute of Medicine Forum on Neuroscience and Nervous System Disorders. 
“Introduction.” Venture Philanthropy Strategies to Support Translational 
Research: Workshop Summary. National Academies Press, 2009.  
b. Available from: https://www.ncbi.nlm.nih.gov/books/NBK45135/. 
7. Strategies for Navigating Intellectual 
Property:https://www.ncbi.nlm.nih.gov/books/NBK50980/.   
8. Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and 
Individualized Therapies: Workshop Summary 
a. Institute of Medicine Forum on Drug Discovery, Development, and Translation. 
Breakthrough Business Models: Drug Development for Rare and Neglected 
Diseases and Individualized Therapies: Workshop Summary. National Academies 
Press, 2009. 
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